scholarly journals Translational Research on Breast Cancer: miRNA, siRNA and Immunoconjugates in Conjugation with Nanotechnology for Clinical Studies

10.5772/21710 ◽  
2011 ◽  
Author(s):  
Arutselvan Natarajan ◽  
Senthil Kumar
Keyword(s):  
Breast Cancer ◽  
Translational Research ◽  
Clinical Studies

The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?

2018 ◽  
Vol 18 (6) ◽  
pp. 832-836
Author(s):  
Giuseppe Buono ◽  
Francesco Schettini ◽  
Francesco Perri ◽  
Grazia Arpino ◽  
Roberto Bianco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Translational Research ◽  
Cell Biology ◽  
Cancer Biology ◽  
Hormone Receptors ◽  
Treatment Strategies ◽  
Growth Factor Receptor ◽  
Molecular Heterogeneity ◽  
Therapeutic Implications ◽  
The Impact

Traditionally, breast cancer (BC) is divided into different subtypes defined by immunohistochemistry (IHC) according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches. In this scenario, translational research represents a key strategy to apply knowledge from cancer biology to the clinical setting, through the study of all the tumors “omics”, including genomics, transcriptomics, proteomics, epigenomics, and metabolomics. Importantly, the introduction of new high-throughput technologies, such as next generation sequencing (NGS) for the study of cancer genome and transcriptome, greatly amplifies the potential and the applications of translational research in the oncology field. Moreover, the introduction of new experimental approaches, such as liquid biopsy, as well as new-concept clinical trials, such as biomarker-driven adaptive studies, may represent a turning point for BC translational research. </P><P> It is likely that translational research will have in the near future a significant impact on BC care, especially by giving us the possibility to dissect the complexity of tumor cell biology and develop new personalized treatment strategies.

Preliminary Pre-Clinical studies on the side effects of breast cancer treatment

2021 ◽  
pp. 1-41
Author(s):  
Camila Salata ◽  
Carlos E. deAlmeida ◽  
Samara C. Ferreira-Machado ◽  
Regina C. Barroso ◽  
Liebert P Nogueira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Clinical Studies ◽  
Breast Cancer Treatment

Conference Scene: Advances in breast cancer translational research

2012 ◽  
Vol 1 (3) ◽  
pp. 197-199
Author(s):  
Hatem A Azim ◽  
Fabrice Andre ◽  
Sherene Loi
Keyword(s):  
Breast Cancer ◽  
Translational Research

scholarly journals Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zicong You ◽  
Weijun Zhou ◽  
Junyan Weng ◽  
Haizhan Feng ◽  
Peiqiao Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
T Cell ◽  
Clinical Studies ◽  
Cd8 T Cell ◽  
Delayed Type Hypersensitivity ◽  
Cochrane Library ◽  
Control Group ◽  
Cell Numbers ◽  
Before And After

Abstract Background The E75 and GP2 vaccines are the few therapeutic vaccines targeting HER2 currently under clinical research for patients with breast cancer. Methods Databases, including the Cochrane Library, PubMed, Medline, Embase, and Web of Science, were used to retrieve clinical studies on E75 and GP2 vaccines. Retrieval time was from the beginning of database construction until May 31st, 2021. Results A total of 24 clinical studies were included in this analysis, including 1704 patients in the vaccinated group and 1248 patients in the control group. For the E75 vaccine, there were significant differences between the vaccinated group and the control group in the delayed-type hypersensitivity reaction (SMD = 0.685 95% CI 0.52–0.85, PHeterogeneity = 0.186, PDTH < 0.05) and the change in CD8+ T-cell numbers (SMD = − 0.864, 95% CI − 1.02 to − 0.709, PHeterogeneity = 0.085, PCD8+ T cell < 0.05) before and after injection. For the GP2 vaccine, there was a significant difference between the vaccinated group and the control group in the change in CD8+ T-cell numbers (SMD = − 0.584, 95% CI − 0.803 to − 0.294, PHeterogeneity = 0.397, PCD8+ T cell < 0.05) before and after injection. In addition, the clinical outcomes, including recurrence rate (RR = 0.568, 95% CI 0.444–0.727, PHeterogeneity = 0.955, PRecurrence < 0.05) and disease-free survival rate (RR = 1.149, 95% CI 1.050–1.256, PHeterogeneity = 0.003, PDFS < 0.05), of the E75-vaccinated group were different from those of the control group. However, we found that the overall survival rate with the E75 vaccine (RR = 1.032, 95% CI 0.998–1.067, PHeterogeneity = 0.476, POS > 0.05) was not different between the two groups. Local and systemic toxicity assessments of the two vaccines showed minimal side effects. Conclusions The E75 vaccine was effective and safe in patients with breast cancer. The GP2 vaccine could elicit a strong immune response, but more trials are needed to confirm its clinical efficacy.

Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life(QOL)

2009 ◽  
Vol 01 (02) ◽  
pp. 083
Author(s):  
Kaiser Jamil ◽  
Kalyan Kumar ◽  
S. Hajira Fatima ◽  
Syed Rabbani ◽  
Ravi Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Studies ◽  
Hormonal Status
Sign in / Sign up

Export Citation Format

Share Document